The Future of Pharmaceuticals and Agriculture Transformed by Synthetic Biology: Biotech Innovation Trends in 2026
Editor
Acceleration of Synthetic Biology Commercialization
In 2026, the field of Synthetic Biology has moved beyond the laboratory phase and entered a full-fledged commercialization phase, impacting the entire biotech industry. The global synthetic biology market has reached a scale of $25 billion, a 28% increase compared to 2025, and is expected to maintain an average annual growth rate of 25% until 2030. Particularly in the pharmaceutical, agricultural, chemical, and energy sectors, innovative solutions that replace existing production methods are being launched in succession, promoting fundamental changes in the industrial ecosystem.
Ginkgo Bioworks, headquartered in Boston, USA, recorded a 45% increase in revenue in the fourth quarter of 2025 compared to the same period the previous year, reaching $120 million, proving the potential success of the synthetic biology platform business. The company develops customized microorganisms through an AI-based biological design platform and supplies them to pharmaceutical and chemical companies, currently running over 200 projects simultaneously. Notably, the automated laboratory facility launched at the end of 2025 can develop microbial strains ten times faster than before, attracting industry attention.
The synthetic biology market in Korea is also rapidly growing. Samsung Biologics invested $1.5 billion in a synthetic biology-based biopharmaceutical production line in 2025 and plans to start full-scale commercial production in the first half of 2026. Celltrion is also focusing on developing next-generation biosimilars using synthetic biology technology, increasing its R&D budget by 35% to $800 million compared to the previous year in 2025. Such active investments by domestic biotech companies indicate that Korea is emerging as a major player in the global synthetic biology market.
The core of synthetic biology is the engineering design and creation of biological systems. While traditional biotechnology utilized naturally existing organisms, synthetic biology combines artificially designed biological components to create organisms with new functions. This process integrates technologies such as DNA synthesis, gene editing, and metabolic pathway design, with recent advancements in AI and machine learning significantly improving the design process. As of 2026, the cost of DNA synthesis has dropped to $0.05 per base pair, an 80% decrease compared to 2020.
Paradigm Shift in the Pharmaceutical Industry
The pharmaceutical industry is the field most significantly impacted by synthetic biology. Medicines that are difficult or excessively costly to produce through traditional chemical synthesis methods can now be efficiently produced using microorganisms, fundamentally changing the paradigm of drug development and production. In 2025, the FDA approved 12 drugs produced based on synthetic biology, a 50% increase compared to 2024.
The influence of synthetic biology is particularly notable in the field of rare disease therapeutics. Previously, the development of rare disease treatments was delayed due to low economic feasibility caused by a small number of patients. However, synthetic biology allows for cost-effective production of these treatments. The production cost of rare disease therapeutics using the synthetic biology platform developed by Zymergen (now acquired by Ginkgo Bioworks) is analyzed to be 70% lower than traditional chemical synthesis methods. This cost reduction is expected to expand the rare disease treatment market, with the global market projected to reach $280 billion by 2026.
Synthetic biology also offers new solutions to the problem of antibiotic resistance. As bacteria resistant to existing antibiotics increase, the need for new antibiotic development grows. Synthetic biology is developing antimicrobial substances with completely new mechanisms of action. Three synthetic biology-based antibiotics launched at the end of 2025 showed over 95% effectiveness against existing antibiotic-resistant bacteria, drawing attention from medical professionals. Buoyed by these achievements, the synthetic biology-based antibiotic market is expected to grow to $15 billion by 2030.
The use of synthetic biology is expanding in the field of personalized medicine as well. The ability to rapidly develop and produce personalized treatments tailored to the genetic characteristics and disease conditions of individual patients through synthetic biology has significantly increased the feasibility of precision medicine. As of 2026, 40% of ongoing clinical trials for personalized treatments in the US and Europe utilize synthetic biology technology, a significant increase from 15% in 2023.
Synthetic biology is also driving innovation in vaccine development. Following the success of mRNA vaccines in 2025, next-generation vaccine platforms utilizing synthetic biology are being developed in succession. These platforms can develop vaccines for new pathogens ten times faster than before, significantly enhancing pandemic response capabilities. The synthetic biology-based vaccine market is expected to grow rapidly from $8 billion in 2026 to $25 billion by 2030.
Innovation in Agriculture and Industry
In the agricultural sector, synthetic biology is emerging as a key technology for sustainable agriculture. In response to changes in agricultural environments due to climate change and increasing food demand, next-generation agricultural solutions utilizing synthetic biology are being introduced. In 2025, the global market for synthetic biology-based agricultural products recorded $3.5 billion, with an average annual growth rate of 22%. The application of synthetic biology is particularly active in the fields of biological pesticides and fertilizers.
Pivot Bio, headquartered in California, USA, is gaining attention for its nitrogen-fixing microbial fertilizer developed using synthetic biology. This product fixes atmospheric nitrogen around plant roots and converts it into a form that plants can directly use, reducing the use of traditional chemical fertilizers by 30-40%. In 2025, the product’s revenue reached $250 million, and it was used on 15% of corn cultivation areas in the US. The reduction in environmental burden due to decreased chemical fertilizer use, along with the cost-saving effect for farmers, is analyzed to average $1,200 per farm annually.
Synthetic biology is also leading innovation in pest control. With the increase in pests resistant to existing chemical pesticides, the need for new control methods is growing. Biological control agents developed through synthetic biology are gaining attention as alternatives. These biological control agents act only on specific pests, minimizing environmental impact while providing high control effectiveness. As of 2026, the global biological pesticide market is valued at $8.5 billion, with synthetic biology-based products accounting for 25% of the market.
The use of synthetic biology is expanding in crop improvement as well. While traditional genetically modified crops simply introduced external genes, synthetic biology allows for more fundamental improvements by redesigning entire metabolic pathways of crops. Crops with improved traits such as drought resistance, salt tolerance, and increased nutrient content are being developed, with synthetic biology-based improved soybeans commercially cultivated in the US and Brazil in 2025, reporting a 20% increase in yield and a 15% improvement in protein content compared to existing varieties.
In the industrial chemical sector, synthetic biology is establishing itself as a key technology for sustainable production. By producing petroleum-based chemical products through biological methods, carbon emissions can be significantly reduced while maintaining economic viability. In 2025, the market for bio-chemical products utilizing synthetic biology recorded $18 billion, accounting for 3% of the entire chemical industry. The application of synthetic biology technology is particularly active in the fields of bio-plastics, biofuels, and industrial enzymes.
Synthetic biology is also driving innovation in the textile industry. Bio-fibers made by producing spider silk proteins in microorganisms are gaining attention as sustainable textile materials due to their higher strength compared to traditional synthetic fibers and biodegradability. Companies like Bolt Threads in the US and Spiber in Japan are leading this field, with the bio-fiber market expected to reach $1.2 billion by 2026. As major fashion brands emphasize sustainability, demand for bio-fibers is rapidly increasing.
The growth of the synthetic biology industry is supported by continuous technological innovation and increased investment. In 2025, venture capital investment in the global synthetic biology field recorded $8.5 billion, a 30% increase compared to the previous year. Investment in the convergence of AI and synthetic biology technology is particularly surging, with investments in this field expected to exceed $10 billion by 2026. Government support is also expanding, with the US government investing $1.2 billion in synthetic biology research in 2025, and China and the European Union investing $800 million and $600 million, respectively.
However, along with the rapid development of synthetic biology, there are challenges that need to be addressed. Concerns about biosafety persist, and long-term studies on the impact of synthetic biology-created organisms on natural ecosystems are needed. Ethical controversies also continue, making the establishment of an international regulatory framework urgent. As of 2026, major countries such as the US, Europe, and Japan are refining regulatory guidelines for synthetic biology products, and discussions are underway to establish an integrated safety assessment system through international cooperation. If these challenges are appropriately addressed, synthetic biology is expected to become a key driver of the 21st-century bioeconomy, with the potential to grow into a massive $50 billion market by 2030.
